Gastroenterology Research of San Antonio, San Antonio, TX, USA.
University of Texas Health Science Center - San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA.
Therap Adv Gastroenterol. 2015 May;8(3):143-59. doi: 10.1177/1756283X15576462.
Crohn's disease (CD) is a debilitating, systemic inflammatory disorder with both gastrointestinal and extraintestinal manifestations. Its existence predates modern medicine, but its precise etiology remains incompletely understood. Most authorities suggest a multifactorial pathogenesis owing to a mixture of genetic disorders, immunologic dysregulation, microbiota disequilibrium and environmental influences. Of these factors, the overactive immunologic response seen in CD appears to be the most promising target of medical therapy. Biological agents comprise a relatively new class of drugs that can induce and maintain remission in moderate to severe CD, as well as in ulcerative colitis. This review will provide an overview of CD, its history, clinical features, pathophysiology, and treatment options focusing on current and future biological agents with an emphasis on drug development, dosage and administration.
克罗恩病(CD)是一种使人衰弱的全身性炎症性疾病,既有胃肠道表现,也有肠道外表现。这种疾病在现代医学出现之前就已经存在,但确切病因仍不完全清楚。大多数权威人士认为,其发病机制是多种因素共同作用的结果,包括遗传紊乱、免疫失调、微生物失衡和环境影响。在这些因素中,CD 中观察到的过度免疫反应似乎是医学治疗最有希望的靶点。生物制剂是一类相对较新的药物,可诱导和维持中重度 CD 以及溃疡性结肠炎的缓解。本综述将概述 CD 的历史、临床特征、病理生理学和治疗选择,重点介绍当前和未来的生物制剂,并强调药物开发、剂量和给药。